FDA 21 CFR Part 111: GMP Requirements for Dietary Supplement Manufacturers

21 CFR Part 111 — the FDA’s Current Good Manufacturing Practice (cGMP) regulations for dietary supplements — has been in force since 2008. Yet FDA inspection data consistently shows that GMP violations remain the most common basis for Warning Letters to supplement manufacturers. Understanding what Part 111 requires, where manufacturers most frequently fall short, and how it compares to EU GMP standards is essential for any supplement manufacturer operating in or entering the US market.

What Is 21 CFR Part 111?

21 CFR Part 111 is the Code of Federal Regulations section that establishes Current Good Manufacturing Practice requirements for dietary supplements. It was promulgated by FDA under the authority of DSHEA and became fully effective for all manufacturers in June 2010.

Part 111 applies to:

• Manufacturers of dietary supplements sold in the US
• Packagers of dietary supplements
• Holders (warehouses) of dietary supplements
• Importers of dietary supplements into the US

It does not apply to manufacturers of conventional foods, pharmaceuticals, or medical devices — those have separate GMP regulations.

Core Requirements of 21 CFR Part 111

Personnel (Subpart B)

All personnel involved in manufacturing must have education, training, or experience to perform their assigned functions. Supervisors must have the education, training, or experience to supervise. Personnel must follow written procedures for personal hygiene.

Common FDA finding: Training records that document attendance but not competence; supervisors without adequate qualifications for the processes they oversee.

Physical Plant and Grounds (Subpart C)

Facilities must be designed, constructed, and maintained to prevent contamination of dietary supplements. Requirements include:

• Adequate space for manufacturing operations
• Floors, walls, and ceilings that can be adequately cleaned
• Adequate lighting and ventilation
• Pest control programme
• Plumbing and sewage systems that don’t create contamination risk

Equipment and Utensils (Subpart D)

Equipment must be suitable for its intended use, properly installed, cleaned, and maintained. Calibration of measuring instruments is required. Equipment cleaning procedures must be documented and validated.

Common FDA finding: Calibration records missing or out of date; equipment cleaning procedures not validated; equipment used without current maintenance records.

Production and Process Controls (Subpart E)

This is the heart of Part 111. Requirements include:

Master manufacturing record (MMR): For each dietary supplement, a written MMR must specify:

• Name and description of the product
• List of all components and their quantities
• Statement of any intentional overage
• Description of the type of packaging and label
• Specifications for each point, step, or stage in the manufacturing process where control is necessary
• Instructions for manufacturing operations
• Sampling and testing requirements

Batch production record (BPR): For each batch manufactured, a BPR must document:

• Date and time of each step
• Identity of equipment used
• Quantities of each component used
• Actual yield at each step
• Results of any in-process testing
• Identity of the person performing each step

Component testing: Before using any component (raw material) in manufacturing, it must be tested or examined to verify its identity and confirm it meets specifications. For botanical ingredients, identity testing is required for every lot.

Finished product testing: Each batch of finished product must be tested or examined to determine whether it meets product specifications before it is released for distribution.

Laboratory Operations (Subpart F)

Laboratory instruments must be calibrated. Reference standards must be of appropriate quality. Laboratory records must be complete and accurate.

Common FDA finding: Reference standards used beyond their expiry date; laboratory instruments not calibrated; out-of-specification (OOS) results not investigated.

Returned Dietary Supplements (Subpart H)

Procedures for handling returned products, including investigation of the reason for return and disposition decisions.

Product Complaints (Subpart I)

Written procedures for receiving and reviewing consumer complaints. Complaints must be reviewed and investigated. Records of all complaints must be maintained for at least one year.

Records and Recordkeeping (Subpart J)

All records required by Part 111 must be kept for at least one year beyond the shelf life of the product (or two years beyond the date of manufacture if the product has no expiry date). Records must be available for FDA inspection.

Most Common FDA Warning Letter Issues

FDA’s enforcement data shows consistent patterns in Part 111 violations:

1. Failure to establish product specifications: Many manufacturers have specifications for some parameters but not all required by Part 111 (identity, purity, strength, composition, and limits on contaminants).

2. Failure to test components: Identity testing of every component lot is required. Many manufacturers rely on supplier certificates of analysis without conducting independent identity testing.

3. Inadequate batch production records: BPRs that are incomplete, have unexplained corrections, or don’t document all required information.

4. Failure to conduct finished product testing: Products released without testing against specifications.

5. Inadequate investigation of OOS results: OOS results that are invalidated without adequate investigation, or that are not investigated at all.

6. Inadequate complaint handling: Complaints not reviewed, not investigated, or records not maintained.

How Does 21 CFR Part 111 Compare to EU GMP?

For supplement manufacturers supplying both US and EU markets, understanding the differences between Part 111 and EU food safety GMP is important.

Aspect	21 CFR Part 111 (US)	EU Food Safety GMP (ISO 22000/FSSC 22000)
Regulatory basis	DSHEA; FDA regulation	EU Food Safety Regulation (EC) No 852/2004; ISO standards
Certification	No mandatory third-party certification	ISO 22000 or FSSC 22000 certification common
Component testing	Identity testing required for every lot	Risk-based approach; supplier qualification
Finished product testing	Required before release	Required; specific requirements vary
Batch records	Detailed requirements	Detailed requirements (similar)
Qualified Person	No equivalent	No equivalent for food supplements
Inspection	FDA inspects manufacturing sites	National authorities inspect; ISO certification audits

A manufacturing site that is compliant with 21 CFR Part 111 is generally well-positioned for EU food safety GMP compliance, but there are specific EU requirements — particularly around HACCP (Hazard Analysis and Critical Control Points), which is mandatory under EU food law — that may require additional work.

FDA Inspection: What to Expect

FDA inspects dietary supplement manufacturing sites under its routine surveillance programme and in response to consumer complaints, adverse event reports, or import alerts. Inspections are typically unannounced (unlike EU GMP inspections, which are usually announced).

During an FDA inspection:

• The inspector will request your quality manual, SOPs, master manufacturing records, and batch production records
• The inspector will observe manufacturing operations in progress
• The inspector will review laboratory records and equipment calibration records
• The inspector may collect samples for independent testing

At the end of the inspection, the inspector issues a Form 483 listing observations (potential violations). A response to the Form 483 is expected within 15 business days. If violations are serious or the response is inadequate, FDA may issue a Warning Letter.

At Care Europe, we advise supplement manufacturers on GMP compliance for both US (21 CFR Part 111) and EU markets, and we support pre-inspection preparation and FDA response management. Contact us at [email protected].